167 related articles for article (PubMed ID: 35760469)
1. Advanced nccRCC: what therapeutic options in 2022?
Bigot C; Boudier P; Ladoire S; Barthélémy P
Bull Cancer; 2022 May; 109(2S):2S39-2S46. PubMed ID: 35760469
[TBL] [Abstract][Full Text] [Related]
2. [Non-clear cell renal cell carcinoma: clinico-biological characteristics and therapeutic management except surgery].
Thouvenin J; Barthélémy P; Ladoire S
Bull Cancer; 2020 Jun; 107(5S):S56-S65. PubMed ID: 32620208
[TBL] [Abstract][Full Text] [Related]
3. Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the Literature.
John A; Spain L; Hamid AA
Curr Oncol; 2023 Jan; 30(1):923-937. PubMed ID: 36661719
[TBL] [Abstract][Full Text] [Related]
4. Papillary renal cell carcinoma: A review of the current therapeutic landscape.
Courthod G; Tucci M; Di Maio M; Scagliotti GV
Crit Rev Oncol Hematol; 2015 Oct; 96(1):100-12. PubMed ID: 26052049
[TBL] [Abstract][Full Text] [Related]
5. Systemic Therapies for the Management of Non-Clear Cell Renal Cell Carcinoma: What Works, What Doesn't, and What the Future Holds.
Zoumpourlis P; Genovese G; Tannir NM; Msaouel P
Clin Genitourin Cancer; 2021 Apr; 19(2):103-116. PubMed ID: 33358151
[TBL] [Abstract][Full Text] [Related]
6. Advances in non-clear cell renal cell carcinoma management: From heterogeneous biology to treatment options.
Wilson NR; Acikgoz Y; Hasanov E
Int J Cancer; 2024 Mar; 154(6):947-961. PubMed ID: 37823185
[TBL] [Abstract][Full Text] [Related]
7. Non-clear cell renal carcinomas: Review of new molecular insights and recent clinical data.
Barthélémy P; Rioux-Leclercq N; Thibault C; Saldana C; Borchiellini D; Chevreau C; Desmoulins I; Gobert A; Hilgers W; Khalil A; Lemoine N; Schlürmann-Constans F; Négrier S
Cancer Treat Rev; 2021 Jun; 97():102191. PubMed ID: 34015728
[TBL] [Abstract][Full Text] [Related]
8. Start of a New Era: Management of Non-Clear Cell Renal Cell Carcinoma in 2022.
Maughan BL
Curr Oncol Rep; 2022 Sep; 24(9):1201-1208. PubMed ID: 35438388
[TBL] [Abstract][Full Text] [Related]
9. Non-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target?
Albiges L; Molinie V; Escudier B
Oncologist; 2012; 17(8):1051-62. PubMed ID: 22807514
[TBL] [Abstract][Full Text] [Related]
10. The role of immunotherapy treatment in non-clear cell renal cell carcinoma: An analysis of the literature.
Ventriglia J; Passarelli A; Pisano C; Cecere SC; Rossetti S; Feroce F; Forte M; Casartelli C; Tambaro R; Pignata S; Perversi F; Di Napoli M
Crit Rev Oncol Hematol; 2023 Aug; 188():104036. PubMed ID: 37263397
[TBL] [Abstract][Full Text] [Related]
11. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma.
Tannir NM; Plimack E; Ng C; Tamboli P; Bekele NB; Xiao L; Smith L; Lim Z; Pagliaro L; Araujo J; Aparicio A; Matin S; Wood CG; Jonasch E
Eur Urol; 2012 Dec; 62(6):1013-9. PubMed ID: 22771265
[TBL] [Abstract][Full Text] [Related]
12. Advanced papillary renal cell carcinoma: Epidemiology, genomic drivers, current therapies, and ongoing trials.
Sweeney PL; Jang A; Halat SK; Pal SK; Barata PC
Cancer Treat Res Commun; 2022; 33():100639. PubMed ID: 36162322
[TBL] [Abstract][Full Text] [Related]
13. Advanced Non-Clear Cell Kidney Cancer: In Search of Rational Treatment Approaches.
Ornstein MC; Hutson TE
Cancer J; 2020; 26(5):441-447. PubMed ID: 32947312
[TBL] [Abstract][Full Text] [Related]
14. The role of immunotherapy in non-clear cell renal cell carcinoma.
Climent C; Soriano S; Bonfill T; Lopez N; Rodriguez M; Sierra M; Andreu P; Fragio M; Busquets M; Carrasco A; Cano O; Seguí MA; Gallardo E
Front Oncol; 2023; 13():941835. PubMed ID: 36816976
[TBL] [Abstract][Full Text] [Related]
15. Systemic Treatment for Advanced and Metastatic Non-Clear Cell Renal Cell Carcinoma: Examining Modern Therapeutic Strategies for a Notoriously Challenging Malignancy.
Drobner J; Portal D; Runcie K; Yang Y; Singer EA
J Kidney Cancer VHL; 2023; 10(3):37-60. PubMed ID: 37789902
[TBL] [Abstract][Full Text] [Related]
16. [Clinical analysis of non-clear cell renal cell carcinoma].
Ohba K; Asai A; Mitsunari K; Matsuo T; Mochizuki Y; Miyata Y; Sakai H
Hinyokika Kiyo; 2015 Feb; 61(2):43-7. PubMed ID: 25812592
[TBL] [Abstract][Full Text] [Related]
17. The molecular characterization and therapeutic strategies of papillary renal cell carcinoma.
Chen Q; Cheng L; Li Q
Expert Rev Anticancer Ther; 2019 Feb; 19(2):169-175. PubMed ID: 30474436
[No Abstract] [Full Text] [Related]
18. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis.
Campbell MT; Bilen MA; Shah AY; Lemke E; Jonasch E; Venkatesan AM; Altinmakas E; Duran C; Msaouel P; Tannir NM
Eur J Cancer; 2018 Nov; 104():188-194. PubMed ID: 30380460
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity of tumor microenvironment is associated with clinical prognosis of non-clear cell renal cell carcinoma: a single-cell genomics study.
Chen WJ; Cao H; Cao JW; Zuo L; Qu FJ; Xu D; Zhang H; Gong HY; Chen JX; Ye JQ; Gan SS; Zhou W; Zhu DW; Pan XW; Cui XG
Cell Death Dis; 2022 Jan; 13(1):50. PubMed ID: 35017463
[TBL] [Abstract][Full Text] [Related]
20. Real World Data of Diagnosis, Survival, and Treatment Outcomes in Patients With Metastatic Non Clear Cell Renal Cell Carcinoma.
Izarn F; Allignet B; Gille R; Boyle H; Neidhardt EM; Négrier S; Fléchon A
Clin Genitourin Cancer; 2023 Apr; 21(2):e35-e43. PubMed ID: 36272959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]